Get the Stockscreener App
5.36
2.68%
0.14
After Hours:
5.35
-0.01
-0.19%
Edesa Biotech Inc stock is traded at $5.36, with a volume of 127.61K.
It is up +2.68% in the last 24 hours and down -10.07% over the past month.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
See More
Previous Close:
$5.22
Open:
$5.23
24h Volume:
127.61K
Relative Volume:
0.03
Market Cap:
$47.63M
Revenue:
-
Net Income/Loss:
$-7.82M
P/E Ratio:
-4.6751
EPS:
-1.1465
Net Cash Flow:
$-8.00M
1W Performance:
-10.07%
1M Performance:
-10.07%
6M Performance:
+111.02%
1Y Performance:
+137.06%
1-Day Range:
$5.22
$5.41
1-Week Range:
$5.1113
$6.4028
52-Week Range:
$0.72
$9.37
Edesa Biotech Inc Stock (EDSA) Company Profile
Name
Edesa Biotech Inc
Sector
Industry
Phone
(905) 475-1234
Address
100 SPY COURT, MARKHAM, ON
Compare EDSA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EDSA
Edesa Biotech Inc
|
5.36 | 46.38M | 0 | -7.82M | -8.00M | -1.1465 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Edesa Biotech Inc Stock (EDSA) Latest News
Aug PreEarnings: Can Edesa Biotech Inc sustain earnings growth2026 PreEarnings & Consistent Growth Stock Picks - baoquankhu1.vn
Edesa Biotech (EDSA) CEO receives 2,578-share restricted stock grant - Stock Titan
Aug Opening: Will Edesa Biotech Inc announce a stock splitDividend Hike & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Jobs Data: Is Edesa Biotech Inc still a buy after recent gains2026 Big Picture & AI Optimized Trading Strategy Guides - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) Rating Increased to Hold at Wall Street Zen - MarketBeat
Edesa Biotech (NASDAQ: EDSA) 2026 proxy seeks equity plan boost and director votes - Stock Titan
Edesa Biotech Inc. (EDSA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Edesa Biotech to Showcase Positive ARDS Phase 3 Data at ATS 2026 Summit - TipRanks
Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit - GlobeNewswire
Edesa Biotech (NASDAQ:EDSA) Upgraded to Sell at Wall Street Zen - Defense World
Edesa Biotech provides update on EB06 clinical study - TipRanks
Edesa Biotech Confirms Mid-2026 Start for Phase 2 Vitiligo Trial of EB06 - TipRanks
Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment - ChartMill
Gainers Report: Can Edesa Biotech Inc be the next market leader2026 Risk Factors & AI Powered Trade Plan Recommendations - baoquankhu1.vn
If You Invested $1,000 in Edesa Biotech Inc (EDSA) - Stock Titan
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biotech Inc - GuruFocus
PERCEPTIVE ADVISORS LLC Acquires Significant Stake in Edesa Biot - GuruFocus
Volume Recap: Will Edesa Biotech Inc announce a stock split2026 Top Gainers & Weekly High Return Forecasts - baoquankhu1.vn
Bull Bear: Will Edesa Biotech Inc announce a stock splitPortfolio Gains Report & Daily Growth Stock Tips - baoquankhu1.vn
Perceptive Advisors stake: 563,239 shares in EDESA (NASDAQ: EDSA) - Stock Titan
EDSA SEC FilingsEdesa Biotech Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Edesa Biotech (EDSA) president buys 2,000 shares in open market - Stock Titan
Short Interest in Edesa Biotech, Inc. (NASDAQ:EDSA) Expands By 9,253.7% - MarketBeat
Edesa Biotech (EDSA) CEO adds 1,000 shares in open-market buy - Stock Titan
Best Biotech Stocks To Follow Today – March 7th - Defense World
Edesa Biotech’s Paridiprubart Trial Success Spurs Market Optimism - StocksToTrade
Edesa Biotech Gains Ground with Positive Clinical and Financial News - timothysykes.com
Will Edesa Biotech Inc. stock attract more institutional investorsPortfolio Performance Report & Weekly Return Optimization Plans - Naître et grandir
Best Biotech Stocks To Follow TodayMarch 7th - MarketBeat
Edesa Biotech Surges Following Promising Clinical Data in ARDS Treatment - StocksToTrade
Edesa Biotech Advances on Promising Drug Trial Results - timothysykes.com
Velan Capital Investment Management LP Increases Stake in Edesa Biotech Inc - GuruFocus
Edesa Biotech reports FQ1 net loss of $2.2 million - MSN
Price Action: Will Edesa Biotech Inc announce a stock splitJuly 2025 Earnings & High Yield Equity Trading Tips - baoquankhu1.vn
Edesa Biotech (NASDAQ:EDSA) CEO Pardeep Nijhawan Acquires 10,000 Shares - MarketBeat
Edesa Biotech (EDSA) CEO-linked entity adds 10,000 shares in open-market buy - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Aug Mood: Can Edesa Biotech Inc be the next market leaderWatch List & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Why Did EDSA Stock Rally More Than 70% Today? - Stocktwits
FY2026 EPS Forecast for Edesa Biotech Decreased by Analyst - Defense World
CEO-linked entity buys 10,000 Edesa Biotech (EDSA) shares - Stock Titan
Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving PremarketArbutus Biopharma (NA - Benzinga
Edesa Biotech (NASDAQ: EDSA) CEO adds 3,000 shares in open-market purchases - Stock Titan
Point72 group (NASDAQ: EDSA) reports 600,000 shares, 7.2% stake - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Velan Capital details Edesa Biotech (NASDAQ: EDSA) 9.99% stake - Stock Titan
Nijhawan group boosts Edesa Biotech (EDSA) stake to 19.99% in 13D/A - Stock Titan
Edesa Biotech (NASDAQ: EDSA) CEO adds 50,571 shares in open-market buys - Stock Titan
[Form 4] Edesa Biotech, Inc. Insider Trading Activity - Stock Titan
EDSA: Strengthened Phase 3 ARDS Data Shows Significant Reduction in 28-Day Mortality - Research Tree
Edesa Biotech Advances with Promising Phase 3 Outcomes - StocksToTrade
Edesa Biotech Inc Stock (EDSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):